Cargando…
Population pharmacokinetics and dosing of long-acting injectable antipsychotics
Autores principales: | Kim, David D., Barr, Alasdair M., Rafizadeh, Reza, Procyshyn, Ric M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
CMA Joule Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526156/ https://www.ncbi.nlm.nih.gov/pubmed/34467748 http://dx.doi.org/10.1503/jpn.210079 |
Ejemplares similares
-
Atypical antipsychotics, dystonia, and psychotic depression: old solutions for new problems
por: Gazzellone, Matthew J., et al.
Publicado: (2022) -
Metformin for the treatment of antipsychotic-induced metabolic disturbances in people with intellectual and developmental disabilities
por: Stogios, Nicolette, et al.
Publicado: (2023) -
The antipsychotic potential of cannabidiol: clinical implications for patients with psychosis and comorbid cannabis use disorder
por: Garel, Nicolas, et al.
Publicado: (2021) -
Elevated clozapine levels and toxic effects after SARS-CoV-2 vaccination
por: Thompson, Deborah, et al.
Publicado: (2021) -
Mindfulness-based intervention for benzodiazepine deprescription in hemodialysis patients with anxiety and depressive symptoms
por: Garel, Nicolas, et al.
Publicado: (2023)